The FDA has declined approval for Disc Medicine's rare disease therapy, which was previously associated with the commissioner's voucher program. The rejection marks a setback for the company's efforts to bring the treatment to market.
Whole genome sequencing is improving rare disease diagnosis, with studies from Scotland, Sweden, and the Netherlands reporting diagnostic yields around 23% and long-read sequencing matching standard care with 96.4% concordance.
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
Researchers recommend a new long-read DNA test as the first choice for rare genetic disorders, showing a 3% higher diagnosis rate. Separately, a Chinese AI diagnostic system called DeepRare achieved 57.18% accuracy using only patient symptoms, with accuracy exceeding 70% when genetic data is included.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
India said its 2021 rare disease policy expanded Centres of Excellence from 8 to 15 and raised financial assistance to Rs 50 lakh. But rare disease treatment can cost up to Rs 1 crore or more annually.
India is expanding rare disease support under the 2021 policy, with aid up to Rs 50 lakh and 15 Centres of Excellence. Officials also called for local innovation as treatment costs can reach ₹16 crore.
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
South Korea has approved fast-track drug listing for rare disease treatments, reducing the insurance coverage process from 240 days to 100 days. The reform includes post-listing effectiveness evaluations and flexible pricing agreements, aiming to improve patient access to innovative treatments amid ongoing budget concerns.
The artificial intelligence in drug discovery market is projected to grow from USD 3.25 billion in 2026 to USD 10.29 billion by 2031, representing a 25.94% CAGR. AI technologies are accelerating drug discovery timelines, reducing costs, and improving success rates through advanced analytics and machine learning. North America leads market adoption while Asia-Pacific emerges as a high-growth region driven by expanding biotechnology sectors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07147465 |
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients |
RECRUITING | |
| NCT05203250 |
Longitudinal Registry Including Patients Treated With Heavy Particles |
RECRUITING | |
| NCT02938793 |
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors |
TERMINATED | PHASE2 |
| NCT01440218 |
Idiopathic Diseases of Man |
ENROLLING_BY_INVITATION |
